{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:10:59Z","timestamp":1782983459962,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373936"],"award-info":[{"award-number":["82373936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177584","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T21:43:04Z","timestamp":1743716584000},"page":"177584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90\u03b1\/CDK6\/\u03b2-catenin axis"],"prefix":"10.1016","volume":"996","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7650-3059","authenticated-orcid":false,"given":"Jinjun","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177584_bib1","doi-asserted-by":"crossref","first-page":"11099","DOI":"10.1074\/jbc.REV120.011833","article-title":"Post-translational modifications of Hsp90 and translating the chaperone code","volume":"295","author":"Backe","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177584_bib2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s10495-016-1301-y","article-title":"GART mediates the renewal of intestinal epithelial barrier via p38\/p53\/PUMA cascade in colitis","volume":"21","author":"Bai","year":"2016","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejphar.2025.177584_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","article-title":"Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"121","author":"Chaidos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jnci\/djz159","article-title":"Identification and characterization of tumor-initiating cells in multiple myeloma","volume":"112","author":"Gao","year":"2020","journal-title":"Jnci-J Natl Cancer I"},{"key":"10.1016\/j.ejphar.2025.177584_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.trecan.2024.06.002","article-title":"Targeting cancer stem cells in multiple myeloma","volume":"10","author":"Gunes","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejphar.2025.177584_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143523","article-title":"Identification and characterization of multiple myeloma stem cell-like cells","volume":"13","author":"Guo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2025.177584_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2014-11-609230","article-title":"CDK6 is a regulator of stem cells \u2018Egr\u2019 to wake up","volume":"125","author":"Guzman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/leu.2012.80","article-title":"CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients","volume":"26","author":"Hosen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2025.177584_bib9","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Jakubikova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/leu.2012.140","article-title":"CD19-CD45 low\/- CD38 high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2025.177584_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.exphem.2009.11.008","article-title":"A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients","volume":"38","author":"Kuranda","year":"2010","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejphar.2025.177584_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177584_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42360-w","article-title":"Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma","volume":"14","author":"Leung","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177584_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13543776.2021.1829595","article-title":"An updated patent review of anticancer Hsp90 inhibitors (2013-present)","volume":"31","author":"Li","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejphar.2025.177584_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2025.177584_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/leu.2013.184","article-title":"Multifaceted roles of GSK-3 and Wnt\/\u03b2-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"McCubrey","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2025.177584_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-017-0543-0","article-title":"Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC","volume":"13","author":"McKeage","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejphar.2025.177584_bib18","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1002\/ijc.33054","article-title":"The role of CDK6 in cancer","volume":"147","author":"Nebenfuehr","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.177584_bib19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177584_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2025.177584_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2014-02-558114","article-title":"Requirement for CDK6 in MLL-rearranged acute myeloid leukemia","volume":"124","author":"Placke","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells10020225","article-title":"GSK3beta, a master kinase in the regulation of adult stem cell behavior","volume":"10","author":"Racaud-Sultan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177584_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2025.177584_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","article-title":"Identification and expansion of human colon-cancer-initiating cells","volume":"445","author":"Ricci-Vitiani","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2025.177584_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2014-06-584417","article-title":"CDK6 as a key regulator of hematopoietic and leukemic stem cell activation","volume":"125","author":"Scheicher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.562","article-title":"Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties","volume":"5","author":"Shao","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.ejphar.2025.177584_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-018-0885-2","article-title":"Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles","volume":"9","author":"Shi","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejphar.2025.177584_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0615-3","article-title":"Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential","volume":"11","author":"Spaan","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2025.177584_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301264","article-title":"GART functions as a novel methyltransferase in the RUVBL1\/\u03b2-catenin signaling pathway to promote tumor stemness in colorectal cancer","volume":"10","author":"Tang","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.ejphar.2025.177584_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2012.13","article-title":"Understanding cancer stem cell heterogeneity and plasticity","volume":"22","author":"Tang","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2025.177584_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejphar.2025.177584_bib32","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejphar.2025.177584_bib33","doi-asserted-by":"crossref","first-page":"7308-+","DOI":"10.1093\/nar\/gkq595","article-title":"Structural studies of tri-functional human GART","volume":"38","author":"Welin","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2025.177584_bib34","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ejphar.2025.177584_bib35","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","article-title":"RAR\u03b12 expression confers myeloma stem cell features","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.177584_bib36","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.18632\/oncotarget.2388","article-title":"NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2025.177584_bib37","article-title":"Targeting HSP90 as a novel therapy for cancer: mechanistic insights and translational relevance","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177584_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/ctm.ctm_69_16","article-title":"Stemness-related markers in cancer","volume":"3","author":"Zhao","year":"2017","journal-title":"Cancer Transl Med"},{"key":"10.1016\/j.ejphar.2025.177584_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"Induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:29:45Z","timestamp":1762144185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925003383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S0014299925003383"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177584","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90\u03b1\/CDK6\/\u03b2-catenin axis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177584"}}